ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer August 11, 2026 Suha Jhaveri, Bill Warren and Jim Wassil added to ILiAD Board of Directors; Antony Blanc appointed Chief Business Officer Appointments deepen vaccine development expertise and enhance global commercial and strategic leadership
Smarsh Named to Inc. 5000 for the 19th Consecutive Year August 11, 2026 Smarsh continues to lead the industry with sustained AI-driven innovation and growth
GXP-Storage Expands UK Capacity with Third Restricted-Access Facility at Raunds, Northamptonshire August 11, 2026 The company’s third UK facility adds 95,000+ cubic feet of GxP-compliant, environmentally controlled storage capacity and serves as a consolidation point for regulated materials across the UK, EMEA, and beyond.
Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe August 11, 2026 Transaction highlights Advances Alfasigma’s M&A-led global growth strategy, purposely focused on immunology and gastroenterology. Synergy with Alfasigma’s specialty rheumatology portfolio, adding Nordic Pharma’s rheumatoid arthritis business, including the Nordimet® franchise. Expands footprint by adding Canada and Japan; strengthens presence in Europe, with direct operations in 18 countries, with 265 employees. Adds approximately €190 million in 2025 revenue. Financial terms of the transaction are not disclosed.
Naser Taher Named Among Forbes Middle East’s Top 100 CEOs 2026 August 11, 2026 Recognition highlights the MultiBank Group Founder and Chairman’s leadership, global experience and contribution to the financial services industry
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares August 10, 2026 Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has commenced an underwritten public offering of approximately $150 million of its American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the [...]
Point2 Completes $136M Series B Funding with Arm, LB Investment, and Maverick Silicon August 10, 2026 New Funding Further Solidifies Point2’s e‑Tube Technology Platform as the Foundation for Next-Generation AI Data-Center Interconnect
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer August 10, 2026 Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management
AT&T-Led Neutral-Host Network Powers New Connectivity Experience at Davis Wade Stadium August 10, 2026 AT&T customers at Mississippi State University’s Davis Wade Stadium in Starkville are getting a boost in wireless connectivity following the deployment of a new AT&T-led distributed antenna system, or DAS, powered by Airspan’s MobileAccess 6000 Digital platform. Led and owned by AT&T as a neutral-host network, the new DAS is designed to deliver high-capacity, multi-operator [...]
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile August 10, 2026 Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% Both divesiran dose groups showed substantial primary endpoint efficacy; 93.8% response rate at Q6W and 81.3% response rate at Q12W Divesiran was observed to be well tolerated with no new safety findings Phase 3 PV trial evaluating divesiran Q12W vs. placebo anticipated to initiate in 1H’27 Investor conference call and webcast to be held today, August 10, 2026 at 8:00 a.m. ET